Post by Patient Voice

Alex Shved, a 37-year-old Toronto father of two, is desperately trying to access lifileucel — a Health Canada-approved TIL therapy for metastatic melanoma made from a patient's own tumour cells — but can't, because it hasn't yet cleared Canada's public reimbursement system. He's one of several Ontario #melanoma patients in the same position, including two whose OHIP out-of-country applications were rejected, and a 23-year-old hockey player who died while waiting. The stroy underscores a systemic problem: on average, it takes two and a half years for Health Canada-approved drugs to reach public coverage in Canada — longer than any other G7 country. Read more via The Globe and Mail at: https://lnkd.in/ePDUidPk 🔑